State Street Corp Pds Biotechnology Corp Transaction History

State Street Corp

$2.8 Trillion
Q3 2025

A detailed history of State Street Corp transactions in Pds Biotechnology Corp stock. As of the latest transaction made, State Street Corp holds 133,333 shares of PDSB stock, worth $113,333. This represents 0.0% of its overall portfolio holdings.

Number of Shares

133,333

Previous 133,333 -0.0%

Holding current value

$113,333

Previous $177,000 22.6%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$1.63 - $4.11 $35,045 - $88,365	21,500 Added 19.23%	133,333 $217,000
Q3 2024 Nov 14, 2024	SELL	$2.93 - $4.23 $54,791 - $79,101	-18,700 Reduced 14.33%	111,833 $427,000
Q2 2024 Aug 14, 2024	SELL	$2.55 - $4.02 $1.09 Million - $1.72 Million	-426,787 Reduced 76.58%	130,533 $382,000
Q1 2024 May 15, 2024	BUY	$3.85 - $6.59 $20,358 - $34,847	5,288 Added 0.96%	557,320 $2.21 Million
Q4 2023 Feb 14, 2024	BUY	$3.95 - $6.58 $186,009 - $309,858	47,091 Added 9.33%	552,032 $2.74 Million

Q3 2023 Nov 14, 2023	BUY	$4.8 - $6.4 $230,236 - $306,982	47,966 Added 10.5%	504,941 $2.55 Million
Q2 2023 Aug 14, 2023	BUY	$5.03 - $9.9 $1.78 Million - $3.51 Million	354,442 Added 345.69%	456,975 $2.3 Million
Q1 2023 May 15, 2023	BUY	$5.68 - $11.99 $42,600 - $89,925	7,500 Added 7.89%	102,533 $630,000
Q4 2022 Feb 14, 2023	BUY	$3.28 - $13.2 $45,264 - $182,160	13,800 Added 16.99%	95,033 $1.25 Million
Q2 2022 Aug 15, 2022	BUY	$3.05 - $6.68 $14,335 - $31,396	4,700 Added 6.14%	81,233 $297,000
Q1 2022 May 16, 2022	BUY	$4.78 - $8.43 $19,392 - $34,200	4,057 Added 5.6%	76,533 $474,000
Q4 2021 Feb 14, 2022	BUY	$7.76 - $14.35 $73,720 - $136,325	9,500 Added 15.09%	72,476 $587,000
Q3 2021 Nov 15, 2021	BUY	$9.33 - $17.08 $35,454 - $64,903	3,800 Added 6.42%	62,976 $938,000
Q2 2021 Aug 16, 2021	BUY	$4.35 - $12.86 $257,415 - $761,003	59,176 New	59,176 $743,000

About PDS Biotechnology Corp

Ticker PDSB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,458,700
Market Cap $24.2M
Description
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies...

More about PDSB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.

Account

State Street Corp Pds Biotechnology Corp Transaction History